Actelion is part of the Johnson & Johnson Family of Companies. We are leaders in the science and medicine of pulmonary arterial hypertension (PAH), with over 20 years of experience in this devastating cardiovascular disorder.
Find out more about our marketed products and our clinical development pipeline and how we developed Actelion into a leading company in the field of PAH.
Actelion’s products and late-stage development compounds target a number of different diseases.
Actelion has operative affiliates in over 30 countries - explore our global operations.